Blinatumomab Consolidation in Real World
ConditionB-Cell Acute Lymphoblastic Leukaemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedical College of Wisconsin
About this trial
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
1) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2022 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients
Disqualifiers
N/A
Trial population
Patients with B-ALL diagnosed during or after December 2022
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
200 Participants
are grouped into 2 trial groupsGroup A: Patients who received Blinatumomab Therapy
Group B: Patients who did not receive Blinatumomab Therapy
Trial outcomes
Primary outcomes
1
Percentage of participants with complete remission
Complete remission as defined by patients having no lymphoblasts in the marrow or blood
Time frame
5 years or e.g., 1 year after closure of studySecondary outcomes
1
Overall Survival
Percentage of participants overall survival (OS). OS will be calculated from the time of diagnosis of to death from any cause, and patients will be censored if they were alive at the last follow-up
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov